Jiangsu Hengrui Medicine Co., Ltd.

SHSE:600276 Stock Report

Market Cap: CN¥293.5b

Jiangsu Hengrui Medicine Future Growth

Future criteria checks 1/6

Jiangsu Hengrui Medicine is forecast to grow earnings and revenue by 19.6% and 12.9% per annum respectively. EPS is expected to grow by 17.3% per annum. Return on equity is forecast to be 13.4% in 3 years.

Key information

19.6%

Earnings growth rate

17.3%

EPS growth rate

Pharmaceuticals earnings growth18.6%
Revenue growth rate12.9%
Future return on equity13.4%
Analyst coverage

Good

Last updated29 Apr 2024

Recent future growth updates

Recent updates

Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising

Apr 24
Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising

Earnings and Revenue Growth Forecasts

SHSE:600276 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202635,0277,7426,8666,97414
12/31/202529,9446,4485,3055,87924
12/31/202426,2315,4043,6814,44923
3/31/202423,3254,4327,0248,684N/A
12/31/202322,8204,3026,1607,644N/A
9/30/202322,3444,2071,5593,387N/A
6/30/202322,2164,0951,7973,295N/A
3/31/202321,2893,909-3461,331N/A
12/31/202221,2753,906-7271,265N/A
9/30/202221,6523,4961,0382,908N/A
6/30/202222,8363,9821,1443,566N/A
3/31/202224,4554,2712,1024,168N/A
12/31/202125,9064,5302,5544,219N/A
9/30/202128,5206,2771,4232,944N/A
6/30/202129,7236,3344121,554N/A
3/31/202129,1376,5101,2902,088N/A
12/31/202027,7356,3282,8783,432N/A
9/30/202025,7575,8524,5745,195N/A
6/30/202024,5715,5775,1775,741N/A
3/31/202023,8495,4514,3884,933N/A
12/31/201923,2895,3283,2553,817N/A
9/30/201921,9044,8892,8313,332N/A
6/30/201919,6834,5682,4242,899N/A
3/31/201918,5284,3092,2592,706N/A
12/31/201817,4184,0662,2452,774N/A
9/30/201816,2283,8012,2042,336N/A
6/30/201815,2523,5532,3152,518N/A
3/31/201814,5233,3542,0632,433N/A
12/31/201713,8363,217N/A2,547N/A
9/30/201712,8962,988N/A2,928N/A
6/30/201712,1592,848N/A2,666N/A
3/31/201711,5942,716N/A2,630N/A
12/31/201611,0942,589N/A2,593N/A
9/30/201610,7092,529N/A2,653N/A
6/30/201610,2092,425N/A2,517N/A
3/31/20169,7812,309N/A2,444N/A
12/31/20159,3162,172N/A2,277N/A
9/30/20158,8331,970N/A2,021N/A
6/30/20158,3281,817N/A1,818N/A
3/31/20157,9351,673N/A1,695N/A
12/31/20147,4521,516N/A1,574N/A
9/30/20147,1561,429N/A1,497N/A
6/30/20146,7441,356N/A1,585N/A
3/31/20146,4431,292N/A1,320N/A
12/31/20136,2031,238N/A1,365N/A
9/30/20135,9331,199N/A1,252N/A
6/30/20135,7941,162N/A1,182N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600276's forecast earnings growth (19.6% per year) is above the savings rate (2.9%).

Earnings vs Market: 600276's earnings (19.6% per year) are forecast to grow slower than the CN market (24.4% per year).

High Growth Earnings: 600276's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600276's revenue (12.9% per year) is forecast to grow slower than the CN market (14.6% per year).

High Growth Revenue: 600276's revenue (12.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 600276's Return on Equity is forecast to be low in 3 years time (13.4%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.